Hematopoietic cytokines. Current use in cancer therapy

Area of Science:

• Hematology
• Oncology
• Pharmacology

Background:

• Hematopoietic cytokines are increasingly used clinically, with several approved and others in trials.
• Combinations of cytokines remain largely unexplored in clinical settings.
• Knowledge regarding cytokine use with chemotherapy has significantly advanced.

Purpose of the Study:

• To review the literature on cytokine use in supporting standard chemotherapy.
• To examine cytokine applications in marrow failure syndromes and dose intensification.
• To exclude cytokine use in bone marrow transplantation and progenitor cell collection.

Main Methods:

• Literature review focusing on cytokine support for chemotherapy, marrow failure, and dose escalation.
• Analysis of randomized trials assessing cytokine efficacy.
• Exclusion of studies related to bone marrow transplantation and progenitor cell collection.

Main Results:

• Cytokines shorten cytopenia duration and reduce infections with standard chemotherapy.
• Some trials show no improvement in antitumor response, palliation, or survival with cytokines.
• Granulocyte-macrophage colony-stimulating factor shows benefit in high-risk non-Hodgkin lymphoma.
• Cytokines mitigate infectious complications and may reduce transfusion needs in myelodysplastic syndromes.
• Cytokines enable chemotherapy dose escalation, increasing remission rates but not proven survival benefits.
• Cytokines decrease hematopoietic toxicity but are ineffective for dose escalation with certain agents.

Conclusions:

• Cytokines effectively reduce infectious complications and cytopenia in cancer patients undergoing chemotherapy.
• The overall survival and antitumor benefits of cytokine therapy require further validation through randomized trials.
• Cytokines show promise in managing myelodysplastic syndromes and enabling dose-intense chemotherapy regimens.